JavaScript is disabled for your browser. Some features of this site may not work without it.
ECONOMIC EVALUATION OF INTERFERON (a)over-capETA-1A VERSUS INTERFERON (a)over-capETA-1B IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN IRAN